Dihexa for Cognitive Enhancement

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Dihexa, an unapproved research chemical derived from a blood-pressure hormone and used for sharper memory, has never been tested directly in people. Evidence comes from cell and animal studies, mostly by its inventors, three of whose papers were withdrawn for falsified or fabricated data. A human trial of an injectable relative found no meaningful memory benefit in Alzheimer's disease. Safety is largely unknown, with tumor growth the central theoretical concern. (Full Review)

Protocol

Animal-derived estimate
About 22 mg
No established human dose; converted from 2 mg/kg/day oral in rats for a 70 kg adult, not safety-adjusted
Competing approaches
Oral
Popularized by the inventors; oral, topical and injected regimens circulate without published sources
Single or split dosing
Single daily dose
Common practice; no study has compared single and split oral dosing
Time to effect
Memory in rats
Within 8 days
Improved during maze training; the human time course for dihexa is unknown
Brain-wave recordings
Within 9 days
Altered in people injected with fosgonimeton, a related drug the body converts into dihexa

Benefits

Contraindications
  • Active or past cancer, or known precancerous lesions
  • Carriers of activating MET mutations (hereditary papillary renal carcinoma)
  • Pregnancy and breastfeeding
  • People under 18
  • People receiving MET-targeted or EGFR-targeted cancer therapy
Key Interactions
  • Cholinesterase inhibitors (donepezil, rivastigmine)
Theoretical (inferred from mechanism)
  • MET-targeted cancer drugs (capmatinib, crizotinib)
  • EGFR inhibitors (such as osimertinib, erlotinib)
  • Anticholinergic drugs, including over-the-counter sleep aids and antihistamines (diphenhydramine) and bladder drugs (oxybutynin)
  • Renin–angiotensin drugs (ACE inhibitors, such as lisinopril; angiotensin receptor blockers, such as losartan)
  • Growth-promoting agents (somatropin, tesamorelin)
  • Neurotrophic supplements and peptides (lion's mane, Semax)
  • Alcohol

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection-site reactions, eosinophilia, angioedema, other suspected drug-related serious events, tumor growth promotion, long-term toxicity
  • Speculative:

Monitoring

Marker Target Why
Eosinophil count (CBC) 0–500 cells/µL Safety check: rose with a related compound
ALT and AST ALT 7–56 U/L; AST 10–40 U/L Safety check: human liver effects unknown
Serum creatinine 0.6–1.3 mg/dL Safety check: elimination route unknown
Cognitive test score (MoCA or computerized battery) No established target; track change from own baseline Marker expected to change
Home blood pressure Not specified in the ER Human blood-pressure effects unstudied

Cadence: Baseline before starting (two cognitive baselines), repeated at 4 weeks and at the planned trial end (commonly 8 weeks), then every 3 months if use continues; cognitive testing at the same time of day and under similar sleep conditions

Qualitative Assessment

  • Recall of names and recent events
  • Focus during demanding work
  • Sleep quality
  • Mood or anxiety
  • Headache frequency
  • Skin changes at application sites
  • New lumps or unexplained weight loss